We are extremely excited about the data generated from only 4...

We are extremely excited about the data generated from only 4 weeks of treatment. The large reduction in inflammatory acne lesions observed after this short treatment period, is better than the leading topically applied products currently available on the market. We expect to see even greater reductions in acne lesions and continued safety when treatment with BTX 1503 is extended out to 12 weeks.”

Top line data indicated significant reductions in both inflammatory and non-inflammatory lesions and an improvement in patient satisfaction. On average, inflammatory lesions decreased by ~47%by Day 28 of the study. This significant reduction is greater than any other FDA approved topical acne product, for which data is available after 4 weeks of treatment (as outlined below).
Thats being Apiduo and Aczone.

Given that the short study was conducted and could have a better outcome if these trial were conducted for longer duration. This trial was mainly for safety and efficacy and as mentioned all the specified endpoints were met. Please note there is no mention of Permetex being used as it may lead to better results due to higher cannibadol dosage being delivered in the skin/epiderma.